JP2020073515A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020073515A5 JP2020073515A5 JP2019232073A JP2019232073A JP2020073515A5 JP 2020073515 A5 JP2020073515 A5 JP 2020073515A5 JP 2019232073 A JP2019232073 A JP 2019232073A JP 2019232073 A JP2019232073 A JP 2019232073A JP 2020073515 A5 JP2020073515 A5 JP 2020073515A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- weight
- item
- ppm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 129
- 238000000034 method Methods 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 40
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 claims description 35
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 claims description 35
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 34
- 229960004436 budesonide Drugs 0.000 claims description 34
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical group CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 claims description 33
- 239000004094 surface-active agent Substances 0.000 claims description 29
- 239000012535 impurity Substances 0.000 claims description 27
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 23
- 229910052782 aluminium Inorganic materials 0.000 claims description 23
- 238000003860 storage Methods 0.000 claims description 17
- 239000007921 spray Substances 0.000 claims description 15
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- 238000005507 spraying Methods 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 238000000354 decomposition reaction Methods 0.000 claims description 9
- 229940071648 metered dose inhaler Drugs 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000443 aerosol Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 239000003380 propellant Substances 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 claims 2
- FPBWSPZHCJXUBL-UHFFFAOYSA-N 1-chloro-1-fluoroethene Chemical group FC(Cl)=C FPBWSPZHCJXUBL-UHFFFAOYSA-N 0.000 claims 2
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 claims 2
- 239000003599 detergent Substances 0.000 claims 2
- XUCNUKMRBVNAPB-UHFFFAOYSA-N fluoroethene Chemical compound FC=C XUCNUKMRBVNAPB-UHFFFAOYSA-N 0.000 claims 2
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 description 45
- -1 Glutate Chemical compound 0.000 description 35
- 239000003246 corticosteroid Substances 0.000 description 22
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical class C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 16
- 150000003839 salts Chemical class 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 238000012387 aerosolization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940080593 budesonide / formoterol Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 229960002714 fluticasone Drugs 0.000 description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960001664 mometasone Drugs 0.000 description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- PJFHZKIDENOSJB-JIVDDGRNSA-N symbicort inhalation aerosol Chemical compound C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O PJFHZKIDENOSJB-JIVDDGRNSA-N 0.000 description 2
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 229920002943 EPDM rubber Polymers 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229920005557 bromobutyl Polymers 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 229920005556 chlorobutyl Polymers 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960000193 formoterol fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1521456.2A GB201521456D0 (en) | 2015-12-04 | 2015-12-04 | Pharmaceutical composition |
| GB1521456.2 | 2015-12-04 | ||
| GB1615916.2A GB2554092A (en) | 2016-09-19 | 2016-09-19 | Pharmaceutical composition |
| GB1615916.2 | 2016-09-19 | ||
| JP2018528946A JP6899824B2 (ja) | 2015-12-04 | 2016-12-02 | 薬学的組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528946A Division JP6899824B2 (ja) | 2015-12-04 | 2016-12-02 | 薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020073515A JP2020073515A (ja) | 2020-05-14 |
| JP2020073515A5 true JP2020073515A5 (enExample) | 2021-06-10 |
| JP6931383B2 JP6931383B2 (ja) | 2021-09-01 |
Family
ID=57750288
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528946A Active JP6899824B2 (ja) | 2015-12-04 | 2016-12-02 | 薬学的組成物 |
| JP2019232074A Active JP6899889B2 (ja) | 2015-12-04 | 2019-12-23 | 薬学的組成物 |
| JP2019232073A Active JP6931383B2 (ja) | 2015-12-04 | 2019-12-23 | 薬学的組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528946A Active JP6899824B2 (ja) | 2015-12-04 | 2016-12-02 | 薬学的組成物 |
| JP2019232074A Active JP6899889B2 (ja) | 2015-12-04 | 2019-12-23 | 薬学的組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11559505B2 (enExample) |
| EP (4) | EP3383366B2 (enExample) |
| JP (3) | JP6899824B2 (enExample) |
| CN (2) | CN108289843B (enExample) |
| AU (3) | AU2016364650B2 (enExample) |
| BR (2) | BR122020022602B1 (enExample) |
| CA (1) | CA3007050C (enExample) |
| ES (3) | ES2869176T3 (enExample) |
| MX (1) | MX375783B (enExample) |
| WO (1) | WO2017093758A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6899824B2 (ja) | 2015-12-04 | 2021-07-07 | メキシケム フロー エセ・ア・デ・セ・ヴェ | 薬学的組成物 |
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| EP3922240B1 (en) * | 2016-09-19 | 2023-06-21 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition comprising tiotropium bromide |
| WO2018051128A1 (en) | 2016-09-19 | 2018-03-22 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| CN109715148A (zh) * | 2016-09-19 | 2019-05-03 | 墨西哥氟石股份公司 | 药物组合物 |
| CN109789126B (zh) | 2016-09-19 | 2022-08-05 | 墨西哥氟石股份公司 | 药物组合物 |
| PH12019500577B1 (en) * | 2016-09-19 | 2023-09-08 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| CN109771398B (zh) * | 2019-02-25 | 2019-09-20 | 广州南鑫药业有限公司 | 一种帕拉米韦溶液型吸入剂及其制备方法 |
| GB2584686A (en) * | 2019-06-11 | 2020-12-16 | Mexichem Fluor Sa De Cv | Methods |
| CN110840864B (zh) * | 2019-12-20 | 2022-02-22 | 广州健康元呼吸药物工程技术有限公司 | 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品 |
| JP2023511615A (ja) * | 2020-01-28 | 2023-03-20 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 緩衝化医薬製剤を含む加圧定量吸入器 |
| GB202001537D0 (en) * | 2020-02-05 | 2020-03-18 | Consort Medical Plc | Pressurised dispensing container |
| WO2021165348A1 (en) * | 2020-02-20 | 2021-08-26 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| CN116338014A (zh) * | 2021-12-23 | 2023-06-27 | 上海医药工业研究院有限公司 | 一种吸入用药物组合物的组分分离检测方法 |
| FR3137830A1 (fr) * | 2022-07-13 | 2024-01-19 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| US5439670A (en) * | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| IE67185B1 (en) | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| MX9203481A (es) | 1990-10-18 | 1992-07-01 | Minnesota Mining & Mfg | Formulaciones. |
| US6123924A (en) | 1991-09-25 | 2000-09-26 | Fisons Plc | Pressurized aerosol inhalation compositions |
| US7105152B1 (en) | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
| SG48301A1 (en) * | 1991-12-18 | 1998-04-17 | Astra Ab | New combination |
| MY131733A (en) | 1994-12-22 | 2007-08-30 | Astra Ab | Aerosol drug formulations |
| JPH11503352A (ja) | 1995-04-14 | 1999-03-26 | グラクソ、ウェルカム、インコーポレーテッド | プロピオン酸フルチカゾン用計量投与用吸入器 |
| EP1014943B1 (de) | 1997-02-05 | 2002-06-19 | Jago Research Ag | Medizinische aerosolformulierungen |
| SE9703407D0 (sv) * | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| JP2003525842A (ja) | 1997-09-29 | 2003-09-02 | インヘール セラピューティック システムズ， インコーポレイテッド | 計量吸入器における使用のための安定化調製物 |
| US6103266A (en) | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
| US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| DE59904648D1 (de) | 1998-08-04 | 2003-04-24 | Jago Res Ag Muttenz | Medizinische aerosolformulierungen |
| GB9904919D0 (en) | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| GB2392915B (en) | 1999-09-11 | 2004-04-28 | Glaxo Group Ltd | Pharmaceutical formulation of fluticasone propionate |
| US6432415B1 (en) | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
| US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| UA73986C2 (uk) | 2000-05-22 | 2005-10-17 | К'Єзі Фармачеутічі С.П.А. | АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ |
| CN1144582C (zh) | 2000-11-28 | 2004-04-07 | 中国药科大学 | 治疗呼吸系统疾病的无氟里昂药用气雾剂 |
| TWI324934B (en) | 2001-08-28 | 2010-05-21 | Schering Corp | Pharmaceutical compositions for the treatment of asthma |
| SE0200312D0 (sv) * | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel composition |
| GB0207906D0 (en) | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| US8039746B2 (en) | 2002-08-08 | 2011-10-18 | Fujikura Ltd. | Electric connector and cable |
| GB0323684D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0323685D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2006004646A1 (en) | 2004-06-28 | 2006-01-12 | Nektar Therapeutics | Aerosol formulation comprising nicotine salt |
| ES2259915B1 (es) * | 2005-03-15 | 2007-12-16 | Laboratorio Aldo-Union, S.A. | Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion. |
| WO2007020204A2 (en) | 2005-08-12 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate |
| DE102006017320A1 (de) | 2006-04-11 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel |
| EP2117504A1 (en) | 2007-02-09 | 2009-11-18 | Schering Corporation | Stable pharmaceutical drug aerosols |
| WO2009088553A1 (en) * | 2007-10-22 | 2009-07-16 | Board Of Regents, The University Of Texas System | Dry powder drug delivery formulations, methods of use, and devices therefore |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| GB0915106D0 (en) | 2009-08-28 | 2009-10-07 | Glaxo Group Ltd | Process |
| PL2727582T3 (pl) * | 2009-10-02 | 2016-06-30 | Chiesi Farm Spa | Farmaceutyczne formulacje aerozolowe formoterolu i dipropionianu beklometazonu |
| PE20121467A1 (es) | 2009-12-23 | 2012-11-07 | Chiesi Farma Spa | Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica |
| CN105412122A (zh) * | 2010-07-16 | 2016-03-23 | 希普拉有限公司 | 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物 |
| MX2013009525A (es) * | 2011-02-17 | 2013-10-01 | Cipla Ltd | Combinacion de glicopirrolato y un beta2-agonista. |
| GB201108039D0 (en) | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
| GB201117619D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
| GB201117621D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
| CN102362860A (zh) | 2011-10-27 | 2012-02-29 | 江阴长风医药科技有限公司 | 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂 |
| WO2014016548A2 (en) | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
| KR20150096371A (ko) * | 2012-10-23 | 2015-08-24 | 시플라 리미티드 | 티오트로피움 및 히드로플루오로알칸을 포함하는 약학적 조성물 |
| GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
| RS57687B1 (sr) | 2013-12-30 | 2018-11-30 | Chiesi Farm Spa | Pod pritiskom stabilan aerosolni rastvor kompozicije glikopironijum bromida i kombinacije formoterola |
| JP6899824B2 (ja) | 2015-12-04 | 2021-07-07 | メキシケム フロー エセ・ア・デ・セ・ヴェ | 薬学的組成物 |
| CN109715148A (zh) | 2016-09-19 | 2019-05-03 | 墨西哥氟石股份公司 | 药物组合物 |
-
2016
- 2016-12-02 JP JP2018528946A patent/JP6899824B2/ja active Active
- 2016-12-02 ES ES19178832T patent/ES2869176T3/es active Active
- 2016-12-02 CA CA3007050A patent/CA3007050C/en active Active
- 2016-12-02 EP EP16822716.3A patent/EP3383366B2/en active Active
- 2016-12-02 AU AU2016364650A patent/AU2016364650B2/en active Active
- 2016-12-02 CN CN201680071126.5A patent/CN108289843B/zh active Active
- 2016-12-02 WO PCT/GB2016/053812 patent/WO2017093758A1/en not_active Ceased
- 2016-12-02 EP EP19178843.9A patent/EP3556348B1/en active Active
- 2016-12-02 ES ES19178843T patent/ES2866175T3/es active Active
- 2016-12-02 EP EP19178832.2A patent/EP3556347B1/en active Active
- 2016-12-02 MX MX2018006800A patent/MX375783B/es active IP Right Grant
- 2016-12-02 EP EP20169450.2A patent/EP3701940B1/en active Active
- 2016-12-02 ES ES16822716T patent/ES2796177T5/es active Active
- 2016-12-02 CN CN202011316904.7A patent/CN112472689B/zh active Active
- 2016-12-02 BR BR122020022602-1A patent/BR122020022602B1/pt active IP Right Grant
- 2016-12-02 BR BR112018011266-6A patent/BR112018011266B1/pt active IP Right Grant
- 2016-12-02 US US15/781,045 patent/US11559505B2/en active Active
-
2019
- 2019-04-24 AU AU2019202874A patent/AU2019202874C1/en active Active
- 2019-04-24 AU AU2019202875A patent/AU2019202875B2/en active Active
- 2019-09-18 US US16/575,168 patent/US11559507B2/en active Active
- 2019-09-18 US US16/575,069 patent/US11559506B2/en active Active
- 2019-12-23 JP JP2019232074A patent/JP6899889B2/ja active Active
- 2019-12-23 JP JP2019232073A patent/JP6931383B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020073515A5 (enExample) | ||
| JP2020073516A5 (enExample) | ||
| JP6931383B2 (ja) | 薬学的組成物 | |
| JP7228726B2 (ja) | 医薬組成物 | |
| EP1014943B1 (de) | Medizinische aerosolformulierungen | |
| JP6781828B2 (ja) | 医薬組成物 | |
| EP1670432B1 (en) | Aerosol formulations comprising formoterol fumarate dihydrate, a propellant, ethanol and optionally a steroid, where the formoterol fumarate dihydrate has a water content of 4.8-4.28% by weight. | |
| JP2002521424A (ja) | 医薬用エーロゾル製剤 | |
| HU208398B (en) | Process for producing pharmaceutical aerosol composition | |
| EP0655237A1 (de) | Medizinische Aerosolformulierung | |
| CN108289842B (zh) | 药物组合物 | |
| EP1670443B1 (en) | Aerosol formulation comprising formoterol in suspension | |
| KR20190084945A (ko) | 약제학적 조성물 | |
| AU2019264005A1 (en) | Pharmaceutical composition comprising salbutamol | |
| CN102238939B (zh) | 药物气溶胶组合物 | |
| US20030113268A1 (en) | Degradation-resistant glucocorticosteroid formulations | |
| KR20000035879A (ko) | 클로로플루오로카본-비함유 모메타손 푸로에이트 에어로졸 제형 | |
| US20020085978A1 (en) | Degradation-resistant glucocorticosteroid formulations | |
| CA2546441C (en) | Novel compounds | |
| AU2002245329A1 (en) | Degradation-resistant glucocorticosteroid formulations |